NOV is not a good buy, at least not yet. Now, if we can see some deeper cost cuts and a significant improvement of free cash flow, I'd be willing to buy. I don't see this happening before 2022, though. The recovery has started but it's slow-going, so it'll take some time to see any concrete results.
There are no replies in this thread yet. Be the first to post a reply below: